![]() Travere Therapeutics Travere Therapeutics is a biopharmaceutical company that focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. | ![]() Genexine Genexine is a biotechnology company focused on the development and commercialization of immunotherapeutics and long-acting biologics. | Kamada Pharmaceuticals Kamada Pharmaceuticals is a company that develops plasma-derived protein therapeutics for orphan indications. | ||
Founding Date | Founding Date 2011 | Founding Date 1999 | Founding Date 2006 | Founding Date 1990 |
Type | Type Public | Type Public | Type Private | Type Public |
Tags | ||||
Locations | Locations San Diego, US HQ Dublin, IE | Locations Seongnam-si, KR HQ New York, US | Locations Corsham, GB HQ | Locations Rehovot, IL HQ Beit Kama, IL |
Employees | Employees 46293% increase | Employees 86 | Employees 96 | Employees 378 |
Valuation ($) | Valuation ($) 1.4 b | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 317 m |
Financial | ||||
Revenue (est.) | Revenue (est.) $233.2m (FY, 2024) | Revenue (est.) ₩4.4b (FY, 2023) | Revenue (est.) N/A | Revenue (est.) $142.5m (FY, 2023) |
Cost of goods | Cost of goods $7.7m (FY, 2024) | Cost of goods ₩583.6m (FY, 2023) | Cost of goods N/A | Cost of goods $61.7m (FY, 2023) |
Gross profit | Gross profit $225.4m (FY, 2024) | Gross profit ₩6b (FY, 2023) | Gross profit N/A | Gross profit $80.8m (FY, 2023) |
Net income | Net income ($321.5m) (FY, 2024) | Net income (₩66.9b) (FY, 2023) | Net income N/A | Net income $8.3m (FY, 2023) |
Funding | ||||
Total funding raised | Total funding raised $ 25m | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 90m |
Genexine is a biotechnology company focused on the development and commercialization of immunotherapeutics and long-acting biologics.
View companyBath ASU (also known as Qualasept) is a pharmaceutical specials manufacturer.
View companyKamada Pharmaceuticals is a company that develops plasma-derived protein therapeutics for orphan indications.
View company